Home » Posts tagged 'imm' (Page 2)
Tag Archives: imm
Brand CEO Alan Green talks ImmuPharma #IMM, Lanstead Investors, #KAZ Minerals & #URA Holdings on VOX Markets podcast
Brand CEO Alan Green talks ImmuPharma #IMM, Lanstead Investors, #KAZ Minerals & #URA Holdings with Justin Waite on the VOX Markets podcast. Interview is 30 minutes 15 seconds in.
Brand CEO Alan Green talks gigs, Watchstone (WTG), Hemogenyx (HEMO) & Immupharma (IMM) on Vox Markets podcast
Brand CEO Alan Green talks gigs, Watchstone Group (WTG), Hemogenyx (HEMO) & Immupharma (IMM) with Justin Waite on the Vox Markets podcast. The interview is 23 minutes in.
Buy Immupharma (IMM) says VectorVest. This pharma stock still offers further upside for the adventurous investor.
AIM listed ImmuPharma (IMM.L) is a drug discovery and development company. The London-based Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. IMM has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company’s drug candidate and is a treatment for lupus, and life threatening auto immune disease. IMM’s cancer treatment, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company’s research operations are in France.
FREE! For free VectorVest analysis on any stock, go to this link here
On September 27th 2017, IMM reported interim results, recording a reduced interim loss of £3m for the half year to June 30. Following a successful £4.1m fundraising in March 2017, IMM now has net assets of £6.4m, up from £5.5m at 31 Dec 2016. The company said that all patients in its Lupuzor study had “now passed the six months stage, with over 26% of patients having now completed the full 12 months.” Subject to approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), Immupharma is now planning ahead in anticipation of the trial’s successful outcome and expects to have the first set of batches ready by the end of Q1 2018. IMM sees a number of routes to market for Lupuzor, which could include a global licensing deal.
Although the IMM share price exploded higher in late September, VectorVest stock graph analysis logged growth in the GRT (Earnings Growth Rate) in mid June, when the shares were trading around 50p. Despite climbing to 93p, IMM still retains a forecasted GRT of 33%, which VectorVest considers to be excellent. Traders should note that the RS (Relative Safety) metric records a fair rating of 0.90 on a scale of 0.00 to 2.00, but with a current VectorVest valuation of 120p per share, in the run up to commercialisation of Lupuzor, IMM shares remain undervalued.
The chart of IMM is shown above in my normal format. Earnings per share (EPS) are shown in the window below the price. The rapid rise of EPS in July 2017 and the resultant revaluation of IMM.L gave 2 ½ months warning of the breakout in price. Remember EPS growth is the engine that drives the share price. From the 2nd to the 6th of October 2017 the advance in price consolidated prior to a break upwards on the 9th October 2017. The probabilities favour this to continue to the VectorVest valuation.
Summary: From time to time the pharmaceutical sector can provide stellar returns, as small pharma companies either bring a groundbreaking drug to market or are acquired by global drug giants. IMM looks to be close to completing the former with Lupuzor, and with a number of other drug candidates in development and a raft of patents, the stock does still appear to offer further upside for the adventurous investor. Speculative buy.
Dr David Paul
October 10th 2017
Readers can examine trading opportunities on IMM and a host of other similar stocks for a single payment of £5.95. This gives access to the VectorVest Risk Free 5-week trial, where members enjoy unlimited access to VectorVest UK & U.S., plus VectorVest University for on-demand strategies and training. Link here to view.
VectorVest Unisearch
On VectorVest a simple search using the Unisearch tool will quickly find shares that are undervalued with good fundamentals that have just issued a Buy recommendation. This will give the active trader a short list of many high probability trading opportunities each week. Traders now have the opportunity to spend five weeks discovering VectorVest’s unique simplicity, automation and independent guidance. Just £5.95 buys a 5 week trial to enable deep exploration, or how the system can assist in smarter trading in as little as 10 minutes a day. Powerful tools. Proven strategies. Unique Perspectives.
Link here for more info and to set up a trial.
European Financial Publishing Limited T/A VectorVest UK (VectorVest) is authorised and regulated by the Financial Conduct Authority under register number 543038. You should remember that the value of investments and the income derived therefrom may fall as well as rise and you may not get back the amount that you invest. Past performance is not a reliable guide to the future. This material is directed only at persons in the UK and is not an offer or invitation to buy or sell securities. If investors are in any doubt of the suitability of an investment given their individual circumstances, they are recommended to contact an investment manager or independent financial adviser who may be able to provide tailored advice. Opinions expressed whether in general or both on the performance of individual securities and in a wider economic context represent the views of VectorVest at the time of preparation. They are subject to change and should not be interpreted as investment advice. VectorVest and connected companies, clients, directors, employees and other associates, may have a position in any security, or related financial instrument, issued by a company or organisation mentioned on this site. European Financial Publishing Limited is a company incorporated in Scotland under Company Number SC357322 with its registered address at Exchange Tower, 19 Canning Street, Edinburgh EH3 8EH. Email: support@VectorVest.com
Quoted Micro 22 May 2017
NEX EXCHANGE
London and south east England residential property developer St Mark Homes (SMAP) says it will in the immediate future focus on homes for sale for less than £600,000, because this is the London help to buy limit. In 2016, revenues fell from £3.1m to £1.34m but the unchanged contribution from joint ventures and a release of negative goodwill of £150,000 – a non-cash item – meant that pre-tax profit improved from £549,000 to £652,000. There is still negative goodwill of £137,000 on the balance sheet which is likely to boost a future financial year. A lower tax charge helped earnings per share to rise from 14.8p to 16.6p. Total dividends were 11% higher at 5p a share. There was a cash outflow from operations in the period. The NAV is £5.8m, following a share issue that raised £690,000 net of costs via an open offer to existing shareholders. That is 131p a share. Finance director Sean Ryan acquired 4,912 shares at an average price of 94p each.
Markets operator WMC Retail Partners (WELL) benefitted from an increased valuation of its Luton market but trading was down on the previous year. In 2016, revenues dipped from £4.31m to £4.23m, including £100,000 of consultancy revenues, and a pre-tax profit of £13,000 was turned into a £58,000 loss. WMC is on course to reopen its Cornish site under the name Cornucopia in July.
Property developer Formation Group (FRM) moved back into profit at the interim stage based on continuing operations. Revenues doubled from £10.2m to £20.2m, while an operating loss of £84,000 was turned into a profit of £48,000. The corresponding period also included a £1.08m write-back of loans secured on past properties. There was £1.58m in the bank at the end of February 2017. The NAV was £10.4m.
Block Energy (BLOK) says that Schlumberger has completed the acquisition of three production sharIng contracts in the Republic of Georgia that are near to Bock’s own interests. This indicates the interest in the region. Roger McMechan has been appointed as technical manager for Block’s interests.
Investment company Early Equity (EEQP) increased its interim loss from £46,000 to £67,000. The NAV fell from £770,000 to £639,000 at the end of February 2017. The value of investments in BWA Group and Alpha Prospects declined and the investment in Devilfish Poker was written off, although it is hoped that there could eventually some value to the shareholding. Yicom Global, a healthcare products supplier primarily focused on China, has been increasing its number of sales agents and sales.
Coinsilium Group Ltd (COIN) says that nano-payments company SatoshiPay has linked up with PayPal so that 200 million users could potentially use its service. Coinsilium has a 12.1% stake in SatoshiPay.
Milamber Ventures (MLVP) has paid £75,000 for a 15% in Essential Learning, which provides apprenticeship training. The UK Apprenticeship Levy is expected to generate £2.8bn to be invested in training. In the nine months to April 2016, revenues were £616,000 and lost nearly £30,000. Share placings at 16p a share and 20p a share raised a total of £75,000.
Wheelsure Holdings (WHLP) has raised £500,000 at 1p a share and it hopes to raise a further £50,000. Management says that the economic climate has delayed sales of its Tracksure rail safety components and Wheelsure is short of cash to develop the business. The cash is needed for marketing, product development and patent protection. There are trials of products in process. Wheelsure is focusing on generating more sales from existing customers while targeting longer-term sales from new customers.
Karoo Energy (KEP) has raised £465,000 at 3p a share. These investors will receive a warrant exercisable at 6p a share for each share they subscribed for. The warrants last for 36 months. The cash will be used for shale gas exploration in Botswana.
AIM
A strong end to the financial year means that Bilby (BILB) expects to report EBITDA of at least £3.6m, compared with a forecast of £3m. The building services provider says that demand was strong at the end of the financial year with some work starting earlier than expected. There is a cash balance of £2.5m. The figures for the year to March 2017 will be reported before the end of June.
Mortice (MORT) has sparked another profit forecast upgrade following a trading statement. House broker finnCap has increased its 2016-17 pre-tax profit forecast from $4.3m to $5m and next year’s forecast has been raised from $6.2m to $7m. Revenues are better than expected and costs have been kept under control. Net debt was $13.6m at the end of March 2017. The facilities management and security divisions both generated much higher revenues.
Gemfields (GEM) has received an unsolicited bid from 47.1% shareholder Pallinghurst Resources. The offer is not generous. Pallinghurst is offering 1.91 of its shares for each Gemfields share. That is equivalent to 38.5p a share or a total value of £211.5m.
Veltyco Group (VLTY) did even better than expected in 2016. Revenues were 7% ahead of forecast at €6.1m. Underlying pre-tax profit was €1.74m and Northland forecasts a 2017 profit of €4.27m, helped by recent acquisitions. The online gaming marketing business has started 2017 strongly.
RNA therapeutics developer Silence Therapeutics (SLN) has gained a European Patent Office grant for its chemical modification technology and expects to use this patent to generate revenues from specific medicines that are already undergoing clinical trials.
A recovery in oil and gas demand has helped Hardide (HDD) in the first half. Revenues increased by 59% to £1.51m. The underlying operating loss fell from £1.02m to £720,000. Production is building up at the new US facility. Sales are yet to come through from the approvals already given by Airbus Group. A $100,000 order has been received from General Electric.
LightwaveRF (LWRF) reported a slightly reduced interim loss on revenues that grew from £804,000 to £1.17m. The loss fell from £384,000 to £333,000. The home automation business has developed technology and it needs to generate higher sales in order to move into profit. A partnership with Google in the voice control area has propelled the share price upwards.
ImmuPharma (IMM) says that the latest clinical trial results show that Lupuzor, a potential treatment for Lupus, has a robust safety profile. The phase III trial of 200 patients has been going on for 52 weeks and the full results should be available in the first quarter of 2018.
Tiso Blackstar Group SE (TBGR) is selling its 22.9% stake in industrial holding company KTH back to the company. The payment of around £86m will be paid over 19 months with £7m due before the end of 2017 and the rest by the end of 2018. Tiso Blackstar will repay its debt of £23m and a special dividend of £2.3m. The rest of the cash will be reinvested in media investments. There are plans to move the listing in South Africa from AltX to the Main Market. The company is also moving its registered office from Malta to the UK.
Management has announced a potential bid for recruitment company InterQuest Group (ITQ) but the independent directors are not impressed. Chisbridge Ltd is offering 42- a share. The two independent directors say the offer undervalues the company.
Brave Bison (BBSN) has approached Zinc Media (ZIN) and merger discussions are underway. Herald Investments has stakes in both companies.
Edenville Energy (EDL), which operates the Rukwa coal project in Tanzania, has signed a letter of intent to supply 1,000t of coal/month and this could increase to 7,000t/month. This should hopefully be followed by a formal coal supply agreement so that deliveries can start in July.
Tissue Regenix (TRX) is in talks to acquire US-based regenerative medicine company CellRight Technologies.
MAIN MARKET
Flying Brands Ltd (FBDU) says that the prospectus relating to the acquisition of kidney stone analysis company Stone Checker Software has been approved by the authorities. A placing has raised £550,000 at 3p a share.
Andrew Hore
Quoted Micro 30 January 2017
NEX / ISDX
There was a sharp improvement in operating profit from £120,006 to £213,657 at Hydro Hotel, Eastbourne (HYDP) in the year to October 2016. Revenues improved from £3.13m to £3.21m, while gross margin jumped from 9.9% to 13.6%. Pre-tax profit rose from £133,576 to £224,352. Improved marketing has helped to boost trade but the hotel will be hit by increases in the national living wage. Further refurbishment is panned at the hotel. Strong cash generation has increased the cash position from £651,000 to £1.39m. The second interim dividend is being raised from 12p a share to 14p a share, taking the total to 21p a share, up from 18p a share.
Rail track technology supplier Wheelsure Holdings (WHLP) reported an increased loss in the year to August 2016 because of higher admin expenses. Pre-tax loss moved from £228,000 to £262,000. Revenues increased by 21% to £290,000 even though London Underground orders have been delayed by budget restrictions. Orders have been received since the year end. Wheelsure has issued shares at 1p in lieu of £14,000 of commission owed to the company’s Italian agent, which has generated the first order for track equipment incorporating Tracksure.
Ashley House (ASH) remained profitable in the six months to October 2016 even though trading conditions were tough and there remains uncertainty about government funding for supported housing. It does appear likely though that there will be increasing demand for extra care housing schemes. Interim revenues were flat at £10.7m and the gross margin was much lower. The underlying pre-tax profit was halved to £200,000. Full year profit is still forecast to rise from £1.2m to £1.5m but this depends on three schemes reaching financial close by April.
Building projects manager and developer Formation Group (FRM) maintained its pre-tax profit at £2.2m in the year to August 2016, even though the recognised profit share from the development at Norwich House in Streatham fell from £2.42m to £1.42m. Group revenues were one-quarter higher at £29.4m helped by sales of apartments at Iverson Road, London N6. There was also a £1.02m post-tax write back relating to past properties. NAV increased from £7.6m to £10.4m. Since the year end, cash has been received from disposal proceeds, which will reduce net debt from £3m.
Mechan Controls (MECP) has appointed administrators from Leonard Curtis to its subsidiary PJO Industrial, following a deterioration in its prospects. PJO supplies mining and pipe laying equipment. Mining demand has been weak. PJO was hit by a bad debt in 2015 and lost £206,000, while net liabilities were £514,000.
Forbes Ventures (FOR) has raised £530,000 from Gravity Investment Group at 0.3p a share. Gravity has a 60.8% shareholding in Forbes. The bulk of the cash will be invested in £500,000 worth of 12%, two-year convertible loan notes in residential care provider Primus Care, where Gravity director Chris Bateman is on the board. The conversion price will be 80% of the fair market value of an ordinary share.
There was further fundraising activity last week. NQ Minerals (NQMI) has raised £125,000 at 7p a share in order to finance working capital. Energy efficiency products supplier Sandal (SAND) has raised £52,000 at 28p a share. Milamber Ventures (MLVP) executive chairman Andy Hasoon has invested a further £16,300 in the technology investment company at 13.55p a share. Property investor Etaireia (ETIP) has generated £10,000 from the issue of shares at 0.09p each.
United Cacao (UCL) has raised further concerns about former chairman Dennis Melka. This involves a number of loans which were not previously disclosed. It also turns out that the small farmer programme has planted 70 hectares and not 194 hectares as said in the interim figures. The Peru-based cacao plantation operator has extended the exclusivity agreement with existing investors, in order to try to secure the long-term financial viability of the business, to 31 March. Cash is being raised from bond issues at large discounts. Just over $515,000 has been raised from the issue of $3.45m of nominal value bonds with a 7% coupon. One of the company’s directors will invest a further $40,000 at 18 cents per $1 bond.
AIM
Scientific instruments manufacturer Judges Scientific (JDG) had a strong end to 2016 and order intake grew organically by 3% during the year. This was too late to benefit the 2016 figures where slow orders and manufacturing problems had led to disappointment and pre-tax profit is expected to fall to £7.1m. Earnings per share will fall by nearly one-quarter to 82.8p a share. That is line with previously downgraded expectations. The year has started with an order book lasting 13.9 weeks and there are positive foreign exchange movements that will help in the recovery. A 2017 pre-tax profit of £8.6m and earnings per share of 102p are forecast, which is still below the level in 2015.
Imaging and radiation detection products developer Kromek Group (KMK) is raising up to £21m via a placing and one-for-30 open offer at 20p a share. Net cash was £2.3m at the end of October 2016 and the additional cash will provide a significant cushion for the company. Kromek is still a couple of years away from making a pre-tax profit but the cash outflow should decline.
Taptica Ltd (TAP) has issued a positive trading statement and this has led to a forecast upgrade for 2016. Earnings per share have been upgraded by 12% to 29.3 cents, which is 150% higher than the forecast was one year ago. Increasing mobile marketing spend by customers means that there should continue to be significant growth.
Beximco Pharmaceuticals (BXP) has formed a joint venture with BioCare Manufacturing in Malaysia. Beximco will own 30% of the joint venture and will provide technical support. The initial product is a metered dose inhaler. Beximco reported a 14% local currency increase in interim revenues but in sterling they rose from £58m to £79.7m, while the growth rate in pre-tax profit was slightly higher with the sterling equivalent rising from £8.2m to £11.6m. The first product is being sold in the US and approvals have been gained for two other products.
Walker Greenbank (WGB) has received a further £1m insurance payment relating to flooding at Standfast & Barracks at the end of 2015. This takes the total insurance payments for the Lancaster fabric printing factory to £14.3m and there could be more to come. The Milton Keynes warehouse has been restocked. Octopus has increased its stake to 13.1%.
Ultrasound training simulators developer MedaPhor (MED) says it still had cash of £1.4m, net of the litigation settlement, which has been formalised with SonoSim Inc. In 2016, revenues grew by 50% to £3.3m, partly thanks to an initial contribution of £850,000 from the acquisition of Inventive Medical. The loss has increased from £1.5m to £2.5m, after settlement costs.
ImmuPharma (IMM) has recruited the 200 patients it requires for its phase III trial for the Lupuzor potential treatment for Lupus. By the end of January, more than 80% of the patients will have been treated for three months. Patients have to be monitored for 12 months so the full trial will not be completed until the first quarter of 2018. So far, there have been no indications that the drug is not safe.
Headway Investment Partners has increased its offer for Ludgate Environmental (LEF) from 16p a share to 16.3p a share, which compares with the latest NAV of 21.7p a share. The bid, though, provides cash up front rather than having to wait for the portfolio to be sold off.
Ascent Resources (AST) has started a well test at Pg-10 at the Petisovci project in Slovenia and an announcement about the results of the test should be published later this week. Henderson took advantage of a share price rise to sell one-fifth of their stake taking it to just below 10% but then almost doubled the number of shares it owns by converting £1m of convertible loan notes into 100 million shares. There are still £8.14m of convertibles in issue.
Ramblers Metals & Mining (RMM) expects to achieve the milling of 1,250 metric tonnes a day by the middle of 2017. Saleable copper of between 5,100 and 5,800 tonnes is forecast to be produced in 2017, along with 4,400 to 5,100 ounces of gold. In 2016, there was 4,174 tonnes of copper and 6,132 ounces of gold produced.
Keras Resources (KRS) has raised £600,000 at 0.35p a share in order to finance exploration at the Klondyke gold project in Australia. Some of the cash will be used to repay a £265,000 loan.
A concept study for the development of the CS natural pozzolan project in Nevada should be completed by the end of the first quarter of 2017. Sunrise Resources (SRES) should have information about the potential timeline for commercial production for the pozzolan, which is more environmentally friendly alternative to Portland cement.
MAIN MARKET
East Africa-focused Rainbow Rare Earths has raised $8m at 10p a share ahead of its standard listing. Demand for the shares was strong. This cash will be invested in the Gakara rare earths project in Burundi. Rainbow requires $2.23m to enable it to commence production in nine months. The main rare earths will be neodymium and praseodymium, which are used in generators, electric vehicles and wind turbines. Rainbow has secured a ten year offtake agreement with thyssenkrupp Raw Materials, which covers the sale of 5,000 tpa of concentrate. Petra Diamonds founder Adonis Pouroulis is chairman of Rainbow, which could move into profit in the year to June 2018.
Andrew Hore
Quoted Micro 8 February 2016
ISDX
Ace Liberty & Stone (ALSP) has launched an open offer at a large discount to the market price. Ace wants to raise up to £3.5m via a one-for-two open offer at 1p a share. The open offer is not underwritten and the minimum subscription level for it to go ahead is £2m before expenses. Shareholders can apply for more than their entitlement. The mid price is currently 3p (2p/4p), having fallen from 3.75p prior to the open offer announcement. There had been a number of trades during January at around 3.75p a share. Prior to the open offer, Ace raised just over £1m at 3p a share. Management says that the cash will enable Ace to buy properties in a higher price bracket and continue to build the portfolio. The latest acceptance date is 22 February.
DXS International (DXSP) reported a 31 % increase in revenues for the first half but the IT supplier to healthcare professionals reported a similar loss. In the six months to October 2015, revenues grew from £1.16m to £1.52m, while the underlying loss was £11,000. That reflects a rise in admin expenses in order to comply with NHS conditions of service. Management says that DXS is generating cash. Annualised revenues are running at £3.4m and DXS is supplying 37 client commissioning groups and is set to win more. There was£308,000 in the bank at the end of October 2015. At 13p (12.5p/13.5p) a share, DXS is valued at £4.3m.
Blockchain technology company investor Coinsilium Group Ltd (COIN) says that its investee company SatoshiPay, which has developed technology that enables online payments of a few pence per transaction, has undergone a beta launch of the platform for web publishers. Coinsillium owns 14.5% of SatoshiPay, having invested a total of €200,000. At 7.5p (6p/9p) a share, Coinsillium is valued at £5.4m.
Carduus Housing (CHPD) has raised a further £1m from an issue of 6.5% unsecured bonds due in 2020 and this takes the total in issue to £3.5m. Carduus is focused on the affordable residential housing sector and it will initially invest in Scotland in areas where rental demand is greater than supply. The purchase of a portfolio of 15 properties was announced last December.
AIM
Immupharma (IMM) has raised £8.3m at 26p a share. However, £3.76m of this cash is subject to a sharing agreement with Lanstead Capital. This appears to effectively be the same as what used to be called an equity swap, so just how much cash the company receives, whether it is more or less than the £3.76m figure, will be dependent on the performance of the share price. The benchmark share price of the agreement is 34.6667p, which is significantly higher than the placing price and the market price. The cash will be paid in 18 instalments but if the share price at the time of the transaction is not as high as 34.6667p then Immupharma will receive less than one-eighteenth of the £3.76m figure. If the share price is higher then the company will receive more. The cash will finance the phase III trial for Lupozur, the potential lupus treatment.
Imperial Innovations (IVO) is raising an additional £100m for investment in new and existing investee companies and it manged to raise the cash at a premium to the market price. The 425p a share placing price was a 8% premium to the market price and a 39% premium to the last reported NAV. The placing was backed by existing shareholders Woodford, Invesco, Lansdowne and Imperial College. Imperial Innovations is estimated to have had cash of around£90m before the placing.
OptiBiotix (OPTI) has raised an additional £1m at 78p a share from Seneca Partners, which has increased its stake to 7.13%. This follows the £1.5m raised at 75p a share at the end of 2015. The cash will help OptiBiotix to invest in the various products and opportunities that it is developing through its microbiome expertise and technology.
TechFinancials Inc (TECH) has entered into a B2C joint venture with Hong Kong-registered developer of online businesses, IBID Holdings. The 51/49 joint venture will operate a B2C binary options brand. TechFinancials will provide the trading platform and other intangible assets for its 51% stake and IBID will inject $300,000 in cash and provide working capital until the joint venture is making a net profit of at least $100,000 a month for three months in a row. It will take three months to integrate the platform into IBID’s systems. This follows a previous joint venture with Optionfortune late last year. The expected improvement in pre-tax profit from £303,000 to £663,000 in 2016 has not been adjusted for the latest joint venture.
Technology-focused investment company MXC Capital Ltd (MXCP) is proposing to launch a tender offer for one in every 142 shares at 3.6p each– slightly higher than the market price at the time of the announcement. Shareholders can tender more than their entitlement but they may be scaled back. Up to £800,000 will be paid back to shareholders. The closing date for the tender is 19 February and it has to be agreed by shareholders at a general meeting. The strategy is to distribute up to one-fifth of realised gains from its portfolio. At the end of August 2015, MXC had £28.4m in cash and in the subsequent months it has invested £22.5m in AIM-quoted companies Castleton Technology, Castle Street Investments, Pinnacle Technology and ECV, as well as unquoted big data analytics company Sagacity Solutions Ltd.
MAIN MARKET
Quarto Group (QRT) has acquired The Harvard Common Press, which publishes cooking and childcare books. This deal will add hundreds of titles, built up over four decades, to Quarto’s back catalogue.
ANDREW HORE